{"id":31624,"date":"2024-11-22T21:09:00","date_gmt":"2024-11-22T21:09:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4564502_AE64502_0"},"modified":"2024-11-22T21:09:00","modified_gmt":"2024-11-22T21:09:00","slug":"boehringer-ingelheim-launches-vetmedin-solution-pimobendan-oral-solution-first-oral-solution-approved-by-the-fda-for-congestive-heart-failure-in-dogs","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=31624","title":{"rendered":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs"},"content":{"rendered":"<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600\" border=\"0\" alt title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li><i>Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime<sup>1<\/sup><\/i><\/li>\n<li><i>Previous studies have shown that&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;could help&nbsp;improve&nbsp;the&nbsp;survival&nbsp;time&nbsp;and quality&nbsp;of&nbsp;life&nbsp;for&nbsp;dogs&nbsp;with&nbsp;congestive&nbsp;heart&nbsp;failure&nbsp;due&nbsp;to&nbsp;myxomatous&nbsp;mitral&nbsp;valve&nbsp;disease (MMVD) or dilated cardiomyopathy (DCM)<sup>2,3<\/sup><\/i><\/li>\n<li><i>The new&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution&nbsp;offers&nbsp;pet&nbsp;owners&nbsp;a&nbsp;convenient,&nbsp;liquid&nbsp;oral&nbsp;treatment&nbsp;option&nbsp;for those dogs that prefer a liquid<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DULUTH, Ga<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 23, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Boehringer Ingelheim,&nbsp;a&nbsp;global leader&nbsp;in&nbsp;animal health, launched&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution, the first&nbsp;oral&nbsp;solution approved&nbsp;by the&nbsp;U.S.&nbsp;Food and Drug Administration&nbsp;(FDA) for&nbsp;the&nbsp;management&nbsp;of congestive&nbsp;heart&nbsp;failure&nbsp;(CHF)&nbsp;in dogs&nbsp;due to MMVD or DCM.<\/p>\n<p>Unfortunately, heart disease in dogs is common, affecting approximately 10 percent of dogs in their lifetime.<i><sup>1<\/sup> <\/i>Most frequently, dogs are affected by myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM), both which may progress to CHF, characterized by the inability of the heart to effectively pump blood throughout the body.<\/p>\n<p>Now&nbsp;pet&nbsp;owners&nbsp;have&nbsp;a&nbsp;convenient,&nbsp;new&nbsp;management&nbsp;option&nbsp;to&nbsp;support&nbsp;the&nbsp;hearts&nbsp;of&nbsp;dogs&nbsp;with CHF:&nbsp;a&nbsp;liquid&nbsp;version of&nbsp;VETMEDIN<sup>\u00ae<\/sup>,&nbsp;one&nbsp;of&nbsp;the&nbsp;leading&nbsp;canine cardiology&nbsp;medications&nbsp;in&nbsp;the&nbsp;world. Previous studies have shown that VETMEDIN<sup>\u00ae<\/sup> could help increase the survival time and quality of life&nbsp;in&nbsp;dogs&nbsp;due&nbsp;to&nbsp;MMVD&nbsp;or&nbsp;DCM.<sup>2,3<\/sup><\/p>\n<p><b>IMPORTANT SAFETY&nbsp;INFORMATION: VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution (pimobendan oral solution) and&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;(pimobendan)&nbsp;Chewable&nbsp;Tablets<\/b><\/p>\n<p>VETMEDIN\u00ae Solution (pimobendan oral solution) and VETMEDIN\u00ae (pimobendan) Chewable Tablets are&nbsp;for&nbsp;use&nbsp;in dogs&nbsp;with clinical&nbsp;evidence&nbsp;of&nbsp;heart&nbsp;failure&nbsp;only&nbsp;and&nbsp;should&nbsp;not&nbsp;be&nbsp;given in case of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. For more information,&nbsp;see&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=974748614&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FVetmedinSolutionPI_2024.pdf&amp;a=full%C2%A0prescribing%C2%A0information%C2%A0for%C2%A0Vetmedin%C2%A0Solution\" target=\"_blank\" rel=\"nofollow noopener\">full&nbsp;prescribing&nbsp;information&nbsp;for&nbsp;Vetmedin&nbsp;Solution<\/a><\/u>&nbsp;or&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3387904468&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin_PI.pdf&amp;a=see%C2%A0full%C2%A0prescribing\" target=\"_blank\" rel=\"nofollow noopener\">see&nbsp;full&nbsp;prescribing<\/a><\/u>&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=2962480092&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin_PI.pdf&amp;a=information%C2%A0for%C2%A0Vetmedin+Chewable%C2%A0Tablets\" target=\"_blank\" rel=\"nofollow noopener\">information&nbsp;for&nbsp;Vetmedin Chewable&nbsp;Tablets<\/a><\/u>&nbsp;or&nbsp;visit&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3681435076&amp;u=https%3A%2F%2Fbi-animalhealth.com%2Fpets%2Fcanine%2Fproducts%2Ftherapeutics%2Fvetmedin&amp;a=Vetmedinclinic.com\" target=\"_blank\" rel=\"nofollow noopener\">Vetmedinclinic.com<\/a><\/u><\/p>\n<p>&#8220;We continue to&nbsp;deliver&nbsp;new&nbsp;innovations rooted&nbsp;in&nbsp;robust&nbsp;clinical&nbsp;evidence to help&nbsp;more&nbsp;pets,&#8221;&nbsp;said Daniel&nbsp;Watkins,&nbsp;VP&nbsp;US&nbsp;Pet&nbsp;Business,&nbsp;Boehringer&nbsp;Ingelheim.&nbsp;&#8220;We&nbsp;know&nbsp;some&nbsp;dogs&nbsp;and&nbsp;pet&nbsp;owners may&nbsp;prefer&nbsp;a&nbsp;liquid&nbsp;medication,&nbsp;especially&nbsp;for&nbsp;smaller dogs.&nbsp;With&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution,&nbsp;an&nbsp;easy-to- use liquid formulation, we can help more dogs with heart disease have longer survival and live better lives.&#8221;<\/p>\n<p>VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution,&nbsp;now&nbsp;available&nbsp;in&nbsp;the&nbsp;U.S.,&nbsp;provides&nbsp;the&nbsp;same&nbsp;dual&nbsp;mode&nbsp;of&nbsp;action&nbsp;as VETMEDIN<sup>\u00ae<\/sup> Chewable Tablets. The flavorless, twice-daily liquid oral solution should be administered directly into the dog&#8217;s mouth.<\/p>\n<p>Since&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;was&nbsp;first&nbsp;introduced&nbsp;25&nbsp;years&nbsp;ago,&nbsp;dogs&nbsp;and&nbsp;their&nbsp;owners&nbsp;around&nbsp;the&nbsp;world&nbsp;have enjoyed more than 1 million years of additional life to love.<sup>4<\/sup> VETMEDIN<sup>\u00ae<\/sup>&nbsp;Chewable Tablets are approved&nbsp;for&nbsp;the&nbsp;management&nbsp;of&nbsp;the&nbsp;signs&nbsp;of&nbsp;mild, moderate,&nbsp;or&nbsp;severe CHF&nbsp;in&nbsp;dogs&nbsp;due&nbsp;to&nbsp;clinical MMVD or DCM. VETMEDIN<sup>\u00ae<\/sup> Chewable Tablets are indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.<\/p>\n<p>Boehringer Ingelheim also offers VETMEDIN<sup>\u00ae<\/sup>-CA1 (pimobendan), which has FDA conditional approval&nbsp;for&nbsp;use&nbsp;in&nbsp;dogs&nbsp;with&nbsp;Stage&nbsp;B2&nbsp;preclinical&nbsp;MMVD&nbsp;\u2013&nbsp;which&nbsp;may&nbsp;enable&nbsp;a&nbsp;delay&nbsp;in&nbsp;the&nbsp;onset of heart failure symptoms.<\/p>\n<p>For&nbsp;more&nbsp;information,&nbsp;visit&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=2054423097&amp;u=http%3A%2F%2Fwww.boehringer-ingelheim.com%2Fanimal-health&amp;a=www.boehringer-ingelheim.com%2Fanimal-health.\" target=\"_blank\" rel=\"nofollow noopener\">www.boehringer-ingelheim.com\/animal-health<u>.<\/u><\/a><\/u><\/p>\n<p><b>IMPORTANT SAFETY&nbsp;INFORMATION: VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution (pimobendan oral solution) and&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;(pimobendan)&nbsp;Chewable&nbsp;Tablets<\/b><\/p>\n<p>VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution&nbsp;and&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;Chewable Tablets&nbsp;are&nbsp;for&nbsp;use&nbsp;in&nbsp;dogs&nbsp;with&nbsp;clinical&nbsp;evidence of heart failure only. The most common side effects reported in field studies were poor appetite, lethargy, diarrhea,&nbsp;dyspnea,&nbsp;azotemia,&nbsp;weakness,&nbsp;and&nbsp;ataxia.&nbsp;VETMEDIN<sup>\u00ae<\/sup>&nbsp;Solution&nbsp;and&nbsp;VETMEDIN<sup>\u00ae<\/sup> Chewable Tablets should not be given in case of hypertrophic cardiomyopathy, aortic stenosis, or any&nbsp;other&nbsp;clinical&nbsp;condition&nbsp;where&nbsp;an&nbsp;augmentation&nbsp;of&nbsp;cardiac&nbsp;output&nbsp;is&nbsp;inappropriate&nbsp;for functional or anatomical reasons. For more information, see <u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=963318711&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FVetmedinSolutionPI_2024.pdf&amp;a=full+prescribing+information\" target=\"_blank\" rel=\"nofollow noopener\">full prescribing information<\/a><\/u><\/p>\n<p>or&nbsp;visit&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3681435076&amp;u=https%3A%2F%2Fbi-animalhealth.com%2Fpets%2Fcanine%2Fproducts%2Ftherapeutics%2Fvetmedin&amp;a=Vetmedinclinic.com\" target=\"_blank\" rel=\"nofollow noopener\">Vetmedinclinic.com<\/a><\/u><\/p>\n<p><b>IMPORTANT&nbsp;SAFETY&nbsp;INFORMATION:&nbsp;VETMEDIN<sup>\u00ae<\/sup>-CA1&nbsp;(pimobendan)<\/b><\/p>\n<p><b>VETMEDIN<sup>\u00ae<\/sup>-CA1&nbsp;(pimobendan)&nbsp;is&nbsp;for use&nbsp;only&nbsp;in&nbsp;dogs&nbsp;with&nbsp;preclinical&nbsp;MMVD&nbsp;that&nbsp;have&nbsp;a moderate&nbsp;or loud&nbsp;mitral&nbsp;murmur&nbsp;due to&nbsp;mitral&nbsp;regurgitation&nbsp;and cardiomegaly&nbsp;(Stage&nbsp;B2&nbsp;MMVD, 2019&nbsp;ACVIM&nbsp;Consensus&nbsp;Statement1).&nbsp;Is a&nbsp;violation&nbsp;of&nbsp;Federal&nbsp;law&nbsp;to use&nbsp;this&nbsp;product&nbsp;other&nbsp;than as&nbsp;directed&nbsp;in&nbsp;the labeling.&nbsp;VETMEDIN-CA1&nbsp;is&nbsp;conditionally&nbsp;approved&nbsp;by FDA&nbsp;pending&nbsp;a&nbsp;full demonstration&nbsp;of&nbsp;effectiveness&nbsp;under&nbsp;application&nbsp;number&nbsp;141-556.&nbsp;<\/b>For&nbsp;more&nbsp;information,&nbsp;see&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=2949195952&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin-CA1_Prescribing_Information.pdf&amp;a=full\" target=\"_blank\" rel=\"nofollow noopener\">full<\/a><\/u>&nbsp;<u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=1966285525&amp;u=https%3A%2F%2Fdocs.boehringer-ingelheim.com%2FPI%2FTheras%2FVetmedin-CA1_Prescribing_Information.pdf&amp;a=prescribing+information\" target=\"_blank\" rel=\"nofollow noopener\">prescribing information<\/a><\/u>&nbsp;or visit <u><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4310394-1&amp;h=3681435076&amp;u=https%3A%2F%2Fbi-animalhealth.com%2Fpets%2Fcanine%2Fproducts%2Ftherapeutics%2Fvetmedin&amp;a=Vetmedinclinic.com\" target=\"_blank\" rel=\"nofollow noopener\">Vetmedinclinic.com<\/a><\/u><\/p>\n<p><b>About&nbsp;Boehringer Ingelheim<\/b><\/p>\n<p>Boehringer&nbsp;Ingelheim is&nbsp;a&nbsp;biopharmaceutical&nbsp;company&nbsp;active in&nbsp;both&nbsp;human and&nbsp;animal&nbsp;health. As one of the industry&#8217;s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire&nbsp;value chain. More&nbsp;than&nbsp;53,500 employees&nbsp;serve&nbsp;over&nbsp;130&nbsp;markets&nbsp;to&nbsp;build a&nbsp;healthier,&nbsp;more sustainable, and equitable tomorrow. Lean more at boehringer-ingelheim.com\/us.<\/p>\n<p><b>About&nbsp;Boehringer Ingelheim&nbsp;\u2013&nbsp;Animal&nbsp;Health&nbsp;business<\/b><\/p>\n<p>Boehringer Ingelheim provides first-in-class innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply&nbsp;connected&nbsp;and&nbsp;strives&nbsp;to&nbsp;make&nbsp;a&nbsp;difference&nbsp;for&nbsp;people,&nbsp;animals, and&nbsp;society.&nbsp;Learn&nbsp;more&nbsp;at boehringer-ingelheim.com\/animal-health.<\/p>\n<p><b>Media&nbsp;Contact:<\/b><\/p>\n<p><span class=\"xn-person\">Chrissy Jones<\/span><br \/>Director, Corporate Affairs Boehringer Ingelheim&nbsp;<br \/><u><a href=\"mailto:christine.jones@boehringer.com\" target=\"_blank\" rel=\"nofollow noopener\">christine.jones@boehringer.com<\/a><\/u><\/p>\n<p>References<br \/><sup>1<\/sup>&nbsp;Keene, Bruce W et al. &#8220;ACVIM consensus guidelines for the diagnosis and treatment of myxomatous&nbsp;mitral&nbsp;valve&nbsp;disease in&nbsp;dogs.&#8221;&nbsp;<i>Journal&nbsp;of&nbsp;Veterinary&nbsp;Internal Medicine&nbsp;<\/i>vol.&nbsp;33,3&nbsp;(2019): 1127-1140. doi:10.1111\/jvim.15488<br \/><sup>2<\/sup> H\u00e4ggstr\u00f6m,&nbsp;J&nbsp;et&nbsp;al.&nbsp;&#8220;Longitudinal&nbsp;analysis&nbsp;of&nbsp;quality&nbsp;of&nbsp;life,&nbsp;clinical,&nbsp;radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving&nbsp;pimobendan&nbsp;or&nbsp;benazepril:&nbsp;the&nbsp;QUEST&nbsp;study.&#8221;&nbsp;<i>Journal&nbsp;of&nbsp;Veterinary&nbsp;Internal&nbsp;Medicine&nbsp;<\/i>vol. 27,6&nbsp;(2013):&nbsp;1441-51. doi:10.1111\/jvim.12181<br \/><sup>3<\/sup>&nbsp;Lombard, Christophe&nbsp;W&nbsp;et&nbsp;al.&nbsp;&#8220;Clinical&nbsp;efficacy&nbsp;of pimobendan&nbsp;versus&nbsp;benazepril&nbsp;for&nbsp;the&nbsp;treatment of acquired atrioventricular valvular disease in dogs.&#8221; <i>Journal of the American Animal Hospital Association <\/i>vol. 42,4 (2006): 249-61. doi:10.5326\/0420249<br \/><sup>4<\/sup>&nbsp;Epidemiologic simulation of Vetmedin usage 1999-2024, based on EPIC 2016 JVIM (MMVD, stage B2),&nbsp;QUEST 2008&nbsp;JVIM&nbsp;(MMVD,&nbsp;stage&nbsp;C),&nbsp;PROTECT 2012&nbsp;JVIM&nbsp;(DCM,&nbsp;stage&nbsp;B2),&nbsp;O`Grady&nbsp;2008&nbsp;JVIM<\/p>\n<p>(DCM,&nbsp;stage&nbsp;C),&nbsp;Fuentes 2002&nbsp;JVIM&nbsp;(DCM&nbsp;stage&nbsp;C)&nbsp;and&nbsp;BI-owned sales&nbsp;data.<\/p>\n<p>VETMEDIN<sup>\u00ae<\/sup>&nbsp;is&nbsp;a&nbsp;registered&nbsp;trademark&nbsp;of&nbsp;Boehringer&nbsp;Ingelheim&nbsp;Vetmedica&nbsp;GmbH, used under license. \u00a92024 Boehringer&nbsp;Ingelheim&nbsp;Animal&nbsp;Health&nbsp;USA&nbsp;Inc.,&nbsp;Duluth, GA.&nbsp;All&nbsp;rights reserved.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have shown that&nbsp;VETMEDIN\u00ae&nbsp;could help&nbsp;improve&nbsp;the&nbsp;survival&nbsp;time&nbsp;and quality&nbsp;of&nbsp;life&nbsp;for&nbsp;dogs&nbsp;with&nbsp;congestive&nbsp;heart&nbsp;failure&nbsp;due&nbsp;to&nbsp;myxomatous&nbsp;mitral&nbsp;valve&nbsp;disease (MMVD) or dilated cardiomyopathy (DCM)2,3 The new&nbsp;VETMEDIN\u00ae&nbsp;Solution&nbsp;offers&nbsp;pet&nbsp;owners&nbsp;a&nbsp;convenient,&nbsp;liquid&nbsp;oral&nbsp;treatment&nbsp;option&nbsp;for those dogs that prefer a liquid DULUTH, Ga, Nov. 23, 2024 \/PRNewswire\/ &#8212; Boehringer Ingelheim,&nbsp;a&nbsp;global leader&nbsp;in&nbsp;animal health, launched&nbsp;VETMEDIN\u00ae&nbsp;Solution, the [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-31624","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=31624\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - My Blog\" \/>\n<meta property=\"og:description\" content=\"Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have shown that&nbsp;VETMEDIN\u00ae&nbsp;could help&nbsp;improve&nbsp;the&nbsp;survival&nbsp;time&nbsp;and quality&nbsp;of&nbsp;life&nbsp;for&nbsp;dogs&nbsp;with&nbsp;congestive&nbsp;heart&nbsp;failure&nbsp;due&nbsp;to&nbsp;myxomatous&nbsp;mitral&nbsp;valve&nbsp;disease (MMVD) or dilated cardiomyopathy (DCM)2,3 The new&nbsp;VETMEDIN\u00ae&nbsp;Solution&nbsp;offers&nbsp;pet&nbsp;owners&nbsp;a&nbsp;convenient,&nbsp;liquid&nbsp;oral&nbsp;treatment&nbsp;option&nbsp;for those dogs that prefer a liquid DULUTH, Ga, Nov. 23, 2024 \/PRNewswire\/ &#8212; Boehringer Ingelheim,&nbsp;a&nbsp;global leader&nbsp;in&nbsp;animal health, launched&nbsp;VETMEDIN\u00ae&nbsp;Solution, the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=31624\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-22T21:09:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs\",\"datePublished\":\"2024-11-22T21:09:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624\"},\"wordCount\":1521,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2486738\\\/Boehringer_Green_Logo.jpg?p=medium600\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624\",\"name\":\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2486738\\\/Boehringer_Green_Logo.jpg?p=medium600\",\"datePublished\":\"2024-11-22T21:09:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2486738\\\/Boehringer_Green_Logo.jpg?p=medium600\",\"contentUrl\":\"https:\\\/\\\/mma.prnasia.com\\\/media2\\\/2486738\\\/Boehringer_Green_Logo.jpg?p=medium600\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=31624#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=31624","og_locale":"en_US","og_type":"article","og_title":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - My Blog","og_description":"Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime1 Previous studies have shown that&nbsp;VETMEDIN\u00ae&nbsp;could help&nbsp;improve&nbsp;the&nbsp;survival&nbsp;time&nbsp;and quality&nbsp;of&nbsp;life&nbsp;for&nbsp;dogs&nbsp;with&nbsp;congestive&nbsp;heart&nbsp;failure&nbsp;due&nbsp;to&nbsp;myxomatous&nbsp;mitral&nbsp;valve&nbsp;disease (MMVD) or dilated cardiomyopathy (DCM)2,3 The new&nbsp;VETMEDIN\u00ae&nbsp;Solution&nbsp;offers&nbsp;pet&nbsp;owners&nbsp;a&nbsp;convenient,&nbsp;liquid&nbsp;oral&nbsp;treatment&nbsp;option&nbsp;for those dogs that prefer a liquid DULUTH, Ga, Nov. 23, 2024 \/PRNewswire\/ &#8212; Boehringer Ingelheim,&nbsp;a&nbsp;global leader&nbsp;in&nbsp;animal health, launched&nbsp;VETMEDIN\u00ae&nbsp;Solution, the [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=31624","og_site_name":"My Blog","article_published_time":"2024-11-22T21:09:00+00:00","og_image":[{"url":"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600","type":"","width":"","height":""}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=31624#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=31624"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs","datePublished":"2024-11-22T21:09:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=31624"},"wordCount":1521,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=31624#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=31624","url":"https:\/\/transmediavictoria.net.au\/?p=31624","name":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=31624#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=31624#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600","datePublished":"2024-11-22T21:09:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=31624#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=31624"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=31624#primaryimage","url":"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600","contentUrl":"https:\/\/mma.prnasia.com\/media2\/2486738\/Boehringer_Green_Logo.jpg?p=medium600"},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=31624#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"Boehringer Ingelheim launches VETMEDIN\u00ae Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/31624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31624"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/31624\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}